Ryan Savitz, who serves as Executive Vice President, Chief Financial Officer, and Chief Business Officer of Dianthus Therapeutics, Inc. (NASDAQ:DNTH), completed a substantial transaction involving the sale of company equity on July 9, 2026. The executive disposed of 31,249 shares of common stock, generating proceeds of approximately $3.16 million. This activity was executed in accordance with a Rule 10b5-1 trading plan that Mr. Savitz established on December 30, 2025. The transaction occurred while the stock was trading near its 52-week high of $102.33, a period marked by a significant 387% return over the preceding year.
Market analysis indicates that shares were trading at $98.59 at the time of the report, with a market capitalization valued at $5.39 billion. According to InvestingPro analysis, the stock appears overvalued relative to its calculated Fair Value. The specific sales were executed across varying price points, with individual transactions ranging from $100.22 to $101.97 per share. Detailed breakdowns of the sales show that 10,354 shares were sold at a weighted average price of $100.22, with prices fluctuating between $99.75 and $100.74. An additional 15,329 shares were sold at a weighted average price of $101.24, with a range of $100.78 to $101.75. The final block consisted of 5,566 shares sold at a weighted average price of $101.97, with prices ranging from $101.95 to $102.15. The aggregate value of these transactions totaled $3,157,150.
Before executing the sale, Mr. Savitz acquired the 31,249 shares through the exercise of stock options. The exercise price for these shares was set at $21.77 per share, resulting in a total cost of $680,290. The vesting schedule for these options was structured in equal monthly installments over a four-year period commencing May 1, 2024, contingent upon Mr. Savitz's continued service to the company. Following the completion of these sales, Mr. Savitz's direct holdings in Dianthus Therapeutics common stock were reduced to zero. However, he maintains an active position in the form of 68,751 stock options.
In parallel with the executive transaction, Dianthus Therapeutics has advanced its clinical development pipeline. The company has initiated the Phase 3 EMERGE trial, which is designed to evaluate claseprubart in patients diagnosed with generalized Myasthenia Gravis. This global, randomized, multicenter trial is structured to enroll approximately 195 participants. Additionally, the company reported positive outcomes from the Phase 3 CAPTIVATE study, which demonstrated a 75% responder rate for claseprubart in patients with CIDP.
Analyst coverage reflects continued interest in the company's prospects. Raymond James reiterated a Strong Buy rating, setting a price target of $125.00. Guggenheim maintained a Buy rating with a $200.00 price target, highlighting a competitive advantage for Dianthus following the halt of a competing drug trial by Sanofi. TD Cowen echoed this sentiment, reiterating a Buy rating and clarifying that the Sanofi trial halt is specific to the molecule and trial, without affecting Dianthus's overall prospects. Wolfe Research maintained an Outperform rating with a $98.00 price target, noting the stock's decline following the Sanofi announcement.